Mabvax Therapeutics Holdings, Inc. Watch

from 10-Q 10 pages Consent Under and Second Amendment to Loan and Security Agreement

from 10-Q 4 pages Memorial Sloan-Kettering Institute for Cancer Research 1275 York Ave. New York, Ny 10065 Re: Side Letter Agreement to the Exclusive License Agreement, Dated June 30, 2008 and Amended on May 11, 2011, Between Mabvax Therapeutics Holdings, Inc. (“Mabvax”) and Sloan-Kettering Institute for Cancer Research (“Ski”) (The “Ski License Agreement”) Dear Sir/Madame, This Side Letter Agreement Relates to the Ski License Agreement (“Side Letter”), Under Which Ski Granted Mabvax an Exclusive License Under Ski’s Rights in the Invention That Is the Subject of the Disclosure Entitled “Polyvalent Conjugate Vaccines for Cancer” (Sk#14491), and Patent Rights Thereon

from 10-Q 3 pages First Amendment to Loan and Security Agreement

from 8-K 54 pages Loan and Security Agreement

from 10-Q/A 21 pages Exclusive License to Unimolecular Vaccine Antibodies

from 10-Q/A 31 pages Research and License Agreement Between Sloan-Kettering Institute for Cancer Research and Mabvax Therapeutics, Inc

from 10-Q/A 46 pages Exclusive License Agreement for Ski’s Technology “Polyvalent Conjugate Vaccines for Cancer”

from S-1/A 31 pages Research and License Agreement Between Sloan-Kettering Institute for Cancer Research and Mabvax Therapeutics, Inc